Bring AI into IVF Labs for smarter embryo selection
Nova IVF Fertility has announced the integration of Artificial Intelligence (AI) into its IVF labs to bring in greater precision and trust to embryo selection. The fertility chain will implement Vita Embryo, an AI-based embryo assessment, across its 120 clinics in 65 cities. This is implemented through Nova IVF’s partnership with South Korea’s AI technology firm Kai Health. The technology will improve pregnancy rates, reduce time of a patient’s IVF cycle, and can bring in much better transparency in the fertility treatment.
“With the usage of Artificial Intelligence, we are looking at improving the chances of successful pregnancies and faster turnaround of the IVF cycle. Improved precision can also reduce the number of embryos needed for transfer, addressing ethical concerns related to multiple pregnancies. We believe that advanced technologies like this should be accessible to all patients in metros and tier II regions, without any additional monetary charges,” said Shobhit Agarwal, CEO, Nova IVF Fertility.
Dr Hyejun Lee, CEO, Kai Health, said, “Our research indicates that with the intervention of AI, the precision of selecting embryos increased by 12 per cent. Our association with Nova IVF Fertility signifies our readiness for global market expansion. We shall continue to focus on technological excellence and clinical impact by partnering with leading IVF networks globally.”
Kai Health attained medical device certification for Vita Embryo in Europe, Singapore, Korea, and India. Clinical tests indicate that AI-powered Vita Embryo can double the accuracy of embryo selection compared to human evaluation, providing couples with a better chance of attaining a successful outcome.
